On May 2, 2022 iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, reported that it will present a poster at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo, May 2-5 (Press release, iBioPharma, MAY 2, 2022, View Source [SID1234613313]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rachel Jordan, PhD, a senior product manager at iBio, will present the poster (#P061), titled "Plant-Made Antibodies Show Superior Glycosylation Homogeneity While Retaining Pharmacokinetic Properties," which highlights:

The production of a single uniform G0 glycosylation pattern, lacking fucose and xylose, of NISTmAb and rituximab when compared to Chinese Hamster Ovary (CHO) cell culture produced antibodies, which contain more heterogeneous glycosylation patterns.

Comparability of in vivo rodent pharmacokinetic profiles for NISTmAb and rituximab produced using mammalian cell culture and the FastPharming System.

How rapid, scalable transient expression in plants of high-quality mAbs for in vivo studies can significantly shorten the time to achieve in vivo proof-of-concept.
More information about producing consistent, high-quality antibodies in the FastPharming System may be accessed in a whitepaper here.

On May 2, 2022 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology company, reported that it will participate in the Goldman Sachs Industrials and Materials Conference being held in New York, NY (Press release, Leidos, MAY 2, 2022, View Source [SID1234613312]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chris Cage, Chief Financial Officer, will engage in a question and answer "fireside chat" on Tuesday, May 10, 2022 at 9:40 a.m. ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for one year afterward.

On May 2, 2022 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, reported it expects to release its first quarter 2022 financial results before markets open on Monday, May 16, 2022 (Press release, Nuvo Pharmaceuticals, MAY 2, 2022, View Source [SID1234613311]). The Company will review the results of the first quarter 2022 in conjunction with the Annual Meeting of Shareholders (Meeting). The Meeting will be held in a virtual-only format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Meeting

The Meeting will take place online via live audio webcast on Monday, May 16, 2022 at 9:00 a.m. ET at www.virtualshareholdermeeting.com/mrv2022. Online access to the meeting will begin at 8:45 a.m. ET. Shareholders will not be able to attend the Meeting in person.

Miravo’s Notice of Meeting, Management Information Circular (Circular) and the accompanying form of proxy (collectively the Meeting Materials) were mailed on or about April 22, 2022. If you have not received your Meeting Materials, you should contact your broker, if you are a non-registered shareholder or contact Broadridge at [email protected], if you are a registered shareholder. The Meeting Materials outline in detail how to participate in the Company’s virtual Meeting. For people who would like to attend the meeting as a guest, details of the Meeting can be found under the Company’s profile on SEDAR – www.sedar.com.

Registered Shareholders

A registered shareholder is a shareholder who holds common shares of the Company (Common Shares) in their own name (that is, not in the name of, or through an Intermediary). A registered shareholder who owns Common Shares on the Record Date (March 28, 2022) may attend the Meeting online, vote shares electronically and submit questions during the Meeting by visiting: www.virtualshareholdermeeting.com/mrv2022. You will need to have your 16-digit Control Number (Control Number) that is found on the proxy accompanying the Circular to participate in the Meeting. If you do not have a Control Number, then you can attend the Meeting as a guest. You can also vote your shares in advance of the Meeting using the internet, by mail and by telephone by following the instructions on the form of proxy.

Voting by Proxy

A registered shareholder who is unable to attend the virtual Meeting, or does not wish to personally cast their vote(s), may authorize another person at the Meeting to vote on their behalf. This is known as voting by proxy. Registered shareholders should follow the instructions on the form of proxy enclosed with the Circular to authorize another person (Appointee) to vote on their behalf at the Meeting. You must provide your Appointee the exact name and eight character appointee identification number to access the Meeting. Valid Appointees may attend the Meeting online, vote shares electronically and submit questions during the Meeting by visiting www.virtualshareholdermeeting.com/mrv2022.

Attending the Meeting as a Non-Registered Holder

Only registered holders of Common Shares, or the persons they appoint as their proxies, are permitted to vote shares and submit questions at the Meeting. In many cases, Common Shares beneficially owned by a holder (Non-Registered Holder) are registered either in the name of an Intermediary or in the name of a Depository. In order for a Non-Registered Holder to vote their Common Shares at the Meeting, they must carefully follow the procedures and instructions received from the Intermediary.

Attending the Meeting as a Guest

Guests, including Non-Registered Holders, can attend the Meeting, but will not have the ability to ask questions or vote during the Meeting. Guests can join the meeting by visiting: www.virtualshareholdermeeting.com/mrv2022.

Technical Assistance during the Meeting

If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the Virtual Shareholder Meeting log in page.

On May 2, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported the presentation of new preclinical data from its differentiated allogeneic cell engineering platform at Keystone Symposia’s Precision Genome Engineering Conference, taking place April 27 – May 1, 2022, in Keystone, Colorado (Press release, Intellia Therapeutics, MAY 2, 2022, View Source [SID1234613310]). The data presented support the development of NTLA-6001, Intellia’s allogeneic CAR-T development candidate targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin lymphoma (cHL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present promising preclinical data that led to the nomination of Intellia’s wholly owned allogeneic development candidate, NTLA-6001, for CD30-expressing hematologic lymphomas. NTLA-6001 is the first candidate using our differentiated allogeneic platform, which leverages a novel combination of sequential, LNP-delivered gene edits to yield T cells shielded from immune rejection," said Intellia Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D. "Our approach to engineering T cells aims to solve key immunological challenges to allogeneicity, while retaining cell attributes necessary for potent and durable tumor killing. We look forward to advancing NTLA-6001 toward IND-enabling activities."

The data shared at Keystone demonstrated that Intellia’s proprietary allogeneic solution created T cells that not only avoided immune recognition by host CD4 and CD8 T cells, but also were protected from NK cell-mediated killing in in vitro and in vivo mouse models. Furthermore, allogeneic T cells engineered sequentially with LNPs retained high viability, cell expansion, memory phenotype, cytotoxic and cytokine secretion characteristics. Intellia’s allogeneic platform can be deployed for TCR-T and CAR-T cell therapy.

As part of these platform advancement efforts, Intellia evaluated multiple CD30 CAR constructs in a series of in vitro and in vivo experiments. The most potent CAR construct showed complete tumor regression and protection from tumor rechallenge in a T cell lymphoma model. This lead allogeneic CAR-T cell candidate, NTLA-6001, is now in preclinical development for cHL and certain CD30+ T cell lymphomas. CD30, the target for NTLA-6001, is a cell surface protein that is often overexpressed in a variety of hematologic cancers, making it an important candidate for CAR-T cell therapy.

The presentation is available on Intellia’s website at www.intelliatx.com.

On May 2, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, reported that on April 29, 2022 it completed the previously announced acquisition of Héra SAS ("HRA") for €1.8 billion, or approximately $1.9 billion based on current exchange rates, in cash, accelerating its position as a leading global consumer self-care company (Press release, Perrigo Company, MAY 2, 2022, View Source [SID1234613309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Perrigo President and CEO, Murray S. Kessler commented, "We are excited to close this acquisition and welcome the talented HRA team to the Perrigo family. Completing this transaction marks the culmination of our three-year transformation plan that has returned Perrigo to its self-care roots. The addition of HRA advances Perrigo’s vision of making lives better with quality affordable self-care products that consumers trust everywhere they are sold. It also accelerates our sales and earnings growth and is expected to enhance our margins. Our global businesses are now more intertwined and unified than ever before as we focus on expanding our geographic reach, driving category penetration and delivering new product innovation that leverages our consumer-centric mindset."